Subclinical signs in LRRK2 mutation carriers

被引:24
|
作者
Johansen, Krisztina K. [1 ,2 ]
White, Linda R. [1 ,2 ]
Farrer, Matthew J. [3 ]
Aasly, Jan O. [1 ,2 ]
机构
[1] St Olavs Univ Hosp, Dept Neurol, N-7006 Trondheim, Norway
[2] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway
[3] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
关键词
Parkinson's disease; G2019S; N1437H; Premotor; Hyposmia; LRRK2-ASSOCIATED PARKINSONS-DISEASE; DOPAMINERGIC DYSFUNCTION; CLINICAL-DIAGNOSIS; PROGRESSION; ACCURACY; FEATURES; PHASE; RISK;
D O I
10.1016/j.parkreldis.2011.04.014
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Several non-motor features have been reported to precede the motor signs of Parkinson's disease (PD) by several years. However, the time of onset of non-motor and motor symptoms is still debated. Healthy individuals carrying a PD-related mutation are candidates for studying the earliest disease signs. Objectives: To describe clinically healthy family members of PD patients carrying a LRRK2 mutation (LRRK2-PD). Methods:A total of 47 family members of LRRK2-PD patients were included in the present study and were screened for the p.G2019S and p.N1437H substitutions in the LRRK2 gene. A standardized case report form was filled out in each case, including general medical evaluation, neurological examination with UPDRS, an olfaction test, mood, sleep and cognitive questionnaires. Results: Thirty-two study participants were positive, and 15 were negative for a LRRK2 mutation. Higher UPDRS motor scores, more frequent reports of urinary problems, and fewer hours of sleep were found in mutation carriers compared to non-carriers. The mutation carriers with UPDRS >= 8 were all aged over 50 years, had shorter overall sleeping hours, more frequent urinary and constipation problems, higher mood scores and body mass index. Deterioration of olfaction was not detected in either group. Conclusion: Healthy LRRK2 mutation carriers presented subclinical parkinsonian motor and non-motor signs in the apparent absence of olfactory loss. Longitudinal studies will determine whether these changes precede alterations detectable by neuroimaging. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:528 / 532
页数:5
相关论文
共 50 条
  • [31] Intact working memory in non-manifesting LRRK2 carriers - an fMRI study
    Thaler, Avner
    Helmich, Rick C.
    Or-Borichev, Ayelet
    van Nuenen, Bart F. L.
    Shapira-Lichter, Irit
    Gurevich, Tanya
    Orr-Urtreger, Avi
    Marder, Karen
    Bressman, Susan
    Bloem, Bastiaan R.
    Giladi, Nir
    Hendler, Talma
    Mirelman, Anat
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2016, 43 (01) : 106 - 112
  • [32] Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease
    Ichinose, Hiroshi
    Inoue, Ken-ichi
    Arakawa, Shinobu
    Watanabe, Yuki
    Kurosaki, Hiroki
    Koshiba, Shoko
    Hustad, Eldbjorg
    Takada, Masahiko
    Aasly, Jan O.
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (01) : 45 - 52
  • [33] Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers
    Helmich, Rick C.
    Thaler, Avner
    van Nuenen, Bart F. L.
    Gurevich, Tanya
    Mirelman, Anat
    Marder, Karen S.
    Bressman, Susan
    Orr-Urtreger, Avi
    Giladi, Nir
    Bloem, Bastiaan R.
    Toni, Ivan
    NEUROLOGY, 2015, 84 (04) : 399 - 406
  • [34] Cerebrospinal Fluid Biomarkers and Clinical Features in Leucine-Rich Repeat Kinase 2 (LRRK2) Mutation Carriers
    Vilas, Dolores
    Shaw, Leslie M.
    Taylor, Peggy
    Berg, Daniela
    Brockmann, Kathrin
    Aasly, Jan
    Marras, Connie
    Pont-Sunyer, Claustre
    Rios, Jose
    Marek, Ken
    Tolosa, Eduardo
    MOVEMENT DISORDERS, 2016, 31 (06) : 906 - 914
  • [35] Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers
    Zhang, Dongling
    Zhou, Liche
    Shi, Yuting
    Liu, Jun
    Wei, Hongjiang
    Tong, Qiqi
    He, Hongjian
    Wu, Tao
    MOVEMENT DISORDERS, 2023, 38 (01) : 138 - 142
  • [36] Nonmotor Symptoms in Healthy Ashkenazi Jewish Carriers of the G2019S Mutation in the LRRK2 Gene
    Mirelman, Anat
    Alcalay, Roy N.
    Pullman, Rachel Saunders
    Yasinovsky, Kira
    Thaler, Avner
    Gurevich, Tanya
    Melia-Santana, Helen
    Raymond, Deborah
    Gana-Weisz, Mali
    Bar-Shira, Anat
    Ozelius, Laurie
    Clark, Lorraine
    Orr-Urtreger, Avi
    Bressman, Susan
    Marder, Karen
    Giladi, Nir
    MOVEMENT DISORDERS, 2015, 30 (07) : 981 - 986
  • [37] Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson’s disease
    Hiroshi Ichinose
    Ken-ichi Inoue
    Shinobu Arakawa
    Yuki Watanabe
    Hiroki Kurosaki
    Shoko Koshiba
    Eldbjorg Hustad
    Masahiko Takada
    Jan O. Aasly
    Journal of Neural Transmission, 2018, 125 : 45 - 52
  • [38] Chetomin rescues pathogenic phenotype of LRRK2 mutation in drosophila
    Chua, Ling Ling
    Ho, Patrick
    Toh, Joanne
    Tan, Eng-King
    AGING-US, 2020, 12 (18): : 18561 - 18570
  • [39] Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice
    Giesert, Florian
    Hofmann, Andreas
    Buerger, Alexander
    Zerle, Julia
    Kloos, Karina
    Hafen, Ulrich
    Ernst, Luise
    Zhang, Jingzhong
    Vogt-Weisenhorn, Daniela Maria
    Wurst, Wolfgang
    PLOS ONE, 2013, 8 (05):
  • [40] The emerging role of LRRK2 in tauopathies
    Herbst, Susanne
    Lewis, Patrick A.
    Morris, Huw R.
    CLINICAL SCIENCE, 2022, 136 (13) : 1071 - 1079